Three female patients on high-dose tirzepatide (15 mg/week) for obesity developed anhedonia-like symptoms — emotional flatness, loss of motivation, diminished interest in exercise and pleasurable activities — despite successful weight loss. Two had no prior psychiatric history. Symptoms resolved with dose reduction to ≤10 mg/week in two patients; the third required adjunctive bupropion. In one patient, re-escalation triggered symptom recurrence without additional weight-loss benefit, while subsequent dose reduction restored motivation while preserving outcomes.
This finding sits at a clinically significant intersection: GLP-1 receptor agonists modulate mesolimbic dopaminergic circuits — the same reward pathways implicated in addiction, motivation, and anhedonia. Preclinical work has long suggested GLP-1 signaling suppresses dopamine release in the nucleus accumbens, which explains both the drug's beneficial reduction of food craving and, at high doses, its potential to blunt reward-seeking broadly. The therapeutic window appears to matter enormously here.
As a three-case series, this carries obvious limitations — no control group, no validated psychometric instruments, and a female-only sample. Causal inference is weak. However, the dose-recurrence-resolution pattern in one patient provides unusually compelling within-patient evidence of a pharmacological mechanism. With tirzepatide now prescribed to millions, even a modest incidence of subclinical anhedonia could affect adherence, mental health, and quality of life at scale. Clinicians should proactively screen for motivational blunting — not just depressive symptoms — during high-dose GLP-1 therapy. This is incremental but practically urgent.
